EmboMedics said it raised a $4.3 million Series A1 round for the bioresorbable embolization microspheres it’s developing. Maple Grove, Minn.-based EmboMedics said it plans to use the proceeds to pursue pre-market approval for a drug-delivery device, co-founder & CEO Omid Souresrafil said in prepared remarks. The infusion is enough to carry the company through 2018, Souresrafil said. […]